Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2019 Earnings Conference Call Transcript

Aug 08, 2019 • 08:30 am ET

Previous

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2019 Earnings Conference Call Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good morning, ladies and gentlemen, and welcome to the Amicus Second Quarter 2019 Results Conference Call and Webcast. Later, we will conduct a question-and-answer session [Operator Instructions]

I would now like to turn the conference over to your host, Ms. Sara Pellegrino, Vice President of Investor Relations and Corporate Communications, you may begin.

Executive
Sara Pellegrino

Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics' Second Quarter 2019, financial results and corporate highlights. Speaking on today's call we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer and Daphne Quimi, Chief Financial Officer. Also joining for Q&A are Dr. Jay Barth Chief Medical Officer; Dr. Hung Do, Chief Science Officer and Dr. Jeff Castelli, Chief portfolio Officer and Head of Gene Therapy.

As referenced on slide two , we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us that any of our plans will be achieved, any or all of the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements, which speak only to the date hereof.

All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof. For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and risk factors section of our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission and the quarterly report on Form 10-Q for the quarter ended June 30, 2019 to be filed today.

At this time, it is my pleasure to turn the call over to John Crowley, Chairman and Chief Executive Officer. John?

Executive
John F. Crowley

Great. Thanks, Sara, and welcome everyone to our second quarter 2019 results conference call. I'm pleased today to host this conference call to describe more fully with our team the great progress that we've made at Amicus during the second quarter and early into the third quarter this year. It was a great quarter for Galafold in what continues to be one of the most successful launches for a rare disease medicine ever. This success for Galafold now puts us on a clear path to achieving our commercial objectives in 2019, but it also lays the foundation for this oral precision medicine to reach as many patients as quickly as possible for many years to come. Galafold continues to be the cornerstone of our success at Amicus and it will also support the advancement of our robust pipeline, including AT-GAA for Pompe